Remus Pharmaceuticals (NSE:REMUS) Mohanram G-Score: 1 (As of Mar. 2026) — Near Median


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
54 GF Score
Price ₹779.25
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Mohanram G-Score?

Remus Pharmaceuticals NSE:REMUS +2.06% 54 Mohanram G-Score is 1 as of Mar. 2026, which is at its 10-year median of 1.00. GuruFocus rates NSE:REMUS with a GF Score™ of 54/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Remus Pharmaceuticals has an G-score of 1. It is a bad or low score, which tends to have negative absolute returns.

The historical rank and industry rank for Remus Pharmaceuticals's Mohanram G-Score or its related term are showing as below:

NSE:REMUS' s Mohanram G-Score Range Over the Past 10 Years
Min: 1   Med: 1   Max: 1
Current: 1

During the past 7 years, the highest Piotroski G-score of Remus Pharmaceuticals was 1. The lowest was 1. And the median was 1.

Remus Pharmaceuticals  (NSE:REMUS) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Remus Pharmaceuticals Mohanram G-Score Related Terms


Remus Pharmaceuticals Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Mohanram G-Score Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A 1.00

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A 1.00

NSE:REMUS vs MCK, CAH, COR: Mohanram G-Score Comparison

For the Medical Distribution subindustry, Remus Pharmaceuticals's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remus Pharmaceuticals Mohanram G-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's Mohanram G-Score falls into.


NSE:REMUS
54GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Remus Pharmaceuticals has an G-score of 1. It is a bad or low score, which tends to have negative absolute returns.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 1 mean?
Remus Pharmaceuticals (NSE:REMUS) has a Mohanram G-Score of 1 as of Mar. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Remus Pharmaceuticals and its competitors. This is near median its historical median of 1.00. Over the past decade, Remus Pharmaceuticals' Mohanram G-Score has ranged from 1.00 to 1.00.
Is Remus Pharmaceuticals' Mohanram G-Score too high?
Remus Pharmaceuticals' current Mohanram G-Score of 1 is near median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 1.00. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Mohanram G-Score compare to MCK and CAH?
Remus Pharmaceuticals' Mohanram G-Score of 1 can be compared against companies in the Medical Distribution industry. Historically, Remus Pharmaceuticals' own Mohanram G-Score has ranged from 1.00 to 1.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Medical Distribution company?
A good Mohanram G-Score depends on the Medical Distribution industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Mohanram G-Score is 1, which is near median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹779.25 — trading 62.4% below its estimated fair value. The current Mohanram G-Score is 1, which is near median its 10-year median of 1.00. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Mohanram G-Score is 1 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹779.25 is trading 62.4% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Mohanram G-Score: 1 (near median its 10-year median of 1.00)
  • GF Value™: ₹2,071.36 vs. price of ₹779.25 (62.4% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score

Get the complete analysis for NSE:REMUS

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹779.25
Price
₹2,071.36
GF Value